CIK 0000875320 · Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 043039129
- Phone
- 6173416393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,307,135
- in 1 filing, $6.3M under 10b5-1 plans
Net −$6,307,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-18 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −368 | $473.68 | $174K | 48,650 |
| 2026-02-18 | LEIDEN JEFFREY M Executive Chairman | Shares withheld for taxes | −2,964 | $483.75 | $1.4M | 38,344 |
| 2026-02-18 | Bunnage Mark E. EVP, Chief Scientific Officer | Sale 10b5-1 | −1,182 | $473.68 | $560K | 8,486 |
| 2026-02-18 | Biller Jonathan EVP and Chief Legal Officer | Sale 10b5-1 | −1,244 | $473.68 | $589K | 15,748 |
| 2026-02-18 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Sale 10b5-1 | −817 | $473.68 | $387K | 20,727 |
| 2026-02-18 | Ambrose Kristen SVP & Chief Accounting Officer | Sale 10b5-1 | −638 | $473.68 | $302K | 7,750 |
| 2026-02-17 | WAGNER CHARLES F JR EVP, CO & FO | Grant or award | +7,365 | 51,080 | ||
| 2026-02-17 | WAGNER CHARLES F JR EVP, CO & FO | Shares withheld for taxes | −2,294 | $483.75 | $1.1M | 48,786 |
| 2026-02-17 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Grant or award 10b5-1 | +5,789 | 51,921 | ||
| 2026-02-17 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes 10b5-1 | −2,294 | $483.75 | $1.1M | 49,627 |
| 2026-02-17 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −609 | $489.46 | $298K | 49,018 |
| 2026-02-17 | Sachdev Amit EVP Chief Patient & Ext Af Off | Grant or award | +5,789 | 71,182 | ||
| 2026-02-17 | Sachdev Amit EVP Chief Patient & Ext Af Off | Shares withheld for taxes | −2,140 | $483.75 | $1.0M | 69,042 |
| 2026-02-17 | McKechnie Duncan EVP, Chief Commercial Officer | Grant or award | +4,962 | 24,490 | ||
| 2026-02-17 | McKechnie Duncan EVP, Chief Commercial Officer | Shares withheld for taxes | −1,148 | $483.75 | $555K | 23,342 |
| 2026-02-17 | LEIDEN JEFFREY M Executive Chairman | Grant or award | +8,269 | 41,308 | ||
| 2026-02-17 | Kewalramani Reshma CEO & President | Grant or award | +16,326 | 149,813 | ||
| 2026-02-17 | Kewalramani Reshma CEO & President | Shares withheld for taxes | −6,554 | $483.75 | $3.2M | 143,259 |
| 2026-02-17 | Bunnage Mark E. EVP, Chief Scientific Officer | Grant or award 10b5-1 | +2,584 | 13,215 | ||
| 2026-02-17 | Bunnage Mark E. EVP, Chief Scientific Officer | Shares withheld for taxes 10b5-1 | −1,110 | $483.75 | $537K | 12,105 |
Page 6 of 10 · 182 trades